News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in August: BTIG Virtual Biotechnology Conference 2020 Tuesday,
View HTML
Toggle Summary ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020
MOUNTAIN VIEW, Calif. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after market close on Monday, August 10, 2020 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis
MOUNTAIN VIEW, Calif. , July 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (NASDAQ: CCXI) today confirmed that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avacopan for the treatment of patients with ANCA-associated vasculitis.
View HTML
Toggle Summary ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
-- Study to be presented at American Association for Cancer Research (AACR) meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD-1/PD-L1 interaction and signaling in vitro and potent anti-tumor effects in animal models -- MOUNTAIN
View HTML
Toggle Summary ChemoCentryx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
MOUNTAIN VIEW, Calif. , June 15, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx , Inc. (Nasdaq: CCXI) announced today the completion of its follow-on offering of 5,200,000 shares of its common stock. ChemoCentryx also announced today that the underwriters of its follow-on offering exercised in full their
View HTML
Toggle Summary ChemoCentryx Prices Public Offering of Common Stock
MOUNTAIN VIEW, Calif. , June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $58.00 per share. The gross proceeds to ChemoCentryx from the offering,
View HTML
Toggle Summary ChemoCentryx Announces Proposed Public Offering of Common Stock
MOUNTAIN VIEW, Calif. , June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of its common stock.  In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to purchase up to an
View HTML
Toggle Summary ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in Oral Plenary Presentations at EULAR and ERA-EDTA Congresses
Pivotal trial demonstrated avacopan’s statistical superiority in sustaining remission at 52 weeks over the glucocorticoid-containing standard-of-care therapy MOUNTAIN VIEW, Calif. , June 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (NASDAQ: CCXI) today announced presentations highlighting
View HTML
Toggle Summary ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
MOUNTAIN VIEW, Calif. and ST GALLEN, CH , May 18, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a forty-six (46) patient Phase II dose-ranging trial in the orphan kidney disorder, primary Focal
View HTML
Toggle Summary ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights
-- On track to file U.S. New Drug Application (NDA) for avacopan in ANCA-associated vasculitis mid-year -- -- Topline data from CCX140 LUMINA-1 Phase II clinical trial in Focal Segmental Glomerulosclerosis (FSGS) expected Q2 -- -- Completed enrollment of the AURORA clinical trial of avacopan in
View HTML